EU Marketing Authorisation submitted for Ebola vaccine regimen
Janssen has submitted two Marketing Authorisation Applications to the EMA for an investigational Ebola vaccine regimen.
List view / Grid view
Janssen has submitted two Marketing Authorisation Applications to the EMA for an investigational Ebola vaccine regimen.
The FDA has approved Sandoz's biosimilar Ziextenzo and the company now intends to launch it in the US as soon as possible this year.
Thirteen winners have been announced for the 2019 CPhI Pharma Awards including Dr Ge Li for ‘CEO of the Year’ and a ‘Lifetime Achievement' award for John Chiminski.
A US appeals court has upheld a ruling that threw out a $2.54 billion jury verdict Merck won against Gilead over hepatitis C treatments.
500,000 regimens of Janssen's investigational Ebola vaccine are to be donated to support the Ebola outbreak response in the Democratic Republic of the Congo.
The UK government will invest £3.5 million to help develop new antibitoic treatments for gonorrhoea and make them available to low- and middle-income countries.
One of the most important challenges of the hydrogen peroxide technology has traditionally been the material compatibility.
Included in this in-depth focus are articles on using vitamins and fatty acids as APIs as well as the trends that have influenced the global excipients market.
29 October 2019 | By Thermo Fisher Scientific
This webinar explored the use of the Thermo Scientific™ handheld Raman analyser TruScan™ RM with TruTools™ on-board chemometrics to verify the identity of challenging raw materials.
A new liquid formulation of hydroxycarbamide to treat sickle cell disease will “enable doctors to personalise doses in children".
Within this issue is an analysis of the impacts that low temperature can have on protein aggregation, a discussion on maintaining the safety and quality of medicines when delivered using drones and an exploration of chromatographic techniques used to identify impurities in radiopharmaceuticals. Other articles focus on regulatory non-compliance, excipients…
A new agreement will allow eligible cystic fibrosis patients in England to have access to CFTR modulators to treat the underlying cause of their disease.
Trikafta is the first approved treatment that is effective for patients 12 years and older with the most common cystic fibrosis mutation.
Priority Review has been granted for [fam-] trastuzumab deruxtecan (DS-8201) for the treatment of HER2-positive metastatic breast cancer.
A drug capsule that can carry insulin and protect them from the harsh environment of the gastrointestinal tract has been developed.